Direct-to-Consumer Drug Advertising Benefits Companies, but Patients Even More


By Merrill Matthews

Analysts at the nonpartisan Congressional Budget Office recently scored Speaker Nancy Pelosi's drug pricing bill, H.R. 3.

The CBO estimates the bill would reduce revenue at America's pharmaceutical companies between $0.5 trillion and $1 trillion over the next decade, dramatically reducing innovation and preventing the creation of important new medicines.

Proponents of Pelosi's plan appear unfazed. Many have used this news to contend that if drug companies simply scale back spending on television commercials and other direct-to-consumer (DTC) advertising, they would make up for losses imposed by Pelosi's plan.

Such suggestions disregard the math and trivialize the importance of drug advertisements.

First, consider the math. Drug companies' DTC advertising spend is on the low side compared to other industries.

The industry only spends about $6 billion annually on direct-to-consumer advertising to patients. That's just 3.2 percent of the $187.5 billion in total U.S. revenue for the top 10 pharmaceutical manufacturers, and only a fraction of the up to $1 trillion in lost revenue over 10 years.

By contrast, companies in the consumer-packaged goods industry spend, on average, about 24 percent of revenue on marketing, tech software spends 15 percent, and banking and finance about 8 percent.

While drug companies underspend on DTC advertising compared to other industries, they overspend on research and development, about 21 percent of total revenue -- more than any other industry. And it's the revenue from the sale of those drugs that funds that R&D.

Next, consider the importance of DTC drug ads.

Commercials serve a vital public health purpose by raising awareness of medical conditions that many patients might not know about.

Consider the famous drug ad for the insomnia medication Rozerem. In this spot, a haggard, sleepless man has a late-night chat with Abraham Lincoln, a talking beaver, and other fantastical figures. These characters are from his dreams -- and in the commercial, they explain how they've missed him since he stopped sleeping.

Nearly two out of three American adults suffer from sleep problems, and insomnia costs the economy billions of dollars a year in lost productivity. That commercial -- which went viral before we had a term for it -- helped raise awareness for a new, effective sleep treatment, which came with much lower addiction risks than existing products. That's an enormous public health win.

Drug ads convey in a concise, compelling way how products may improve health. Indeed, one national survey found that drug advertising prompts about two in three viewers to take concrete action to better manage their health.

Defenders of Pelosi's bill want to lower drug prices and many think eliminating DTC advertising is a way to do that. But advertising is a way companies convey important information to consumers about products that may help them.

The return on investment isn't just to drug companies, it's to people who act on that important medical information.

Merrill Matthews is a resident scholar with the Institute for Policy Innovation in Dallas, Texas. Follow him on Twitter @MerrillMatthews.

More Resources


11/20/2024
What Donald Trump's Revenge Agenda Is Hiding
Look past the flashy and controversial Cabinet nominees to find that Project 2025 is already being implemented

more info


11/20/2024
Make Education Great Again!
Imagine these words as the first speech delivered by the incoming Secretary of Education.Today, I am here to deliver bitter medicine: American education has failed. Teachers and parents, administrato

more info


11/20/2024
Time-Honored Tradition of Blaming the Left for Dem Defeats
This argument is particularly unconvincing this time around. And it doesn't offer a realistic prescription for future success.

more info


11/20/2024
Dems Are Going To Get Younger and More Radical


more info


11/20/2024
The Blurred Line Between X and the Trump Administration
Forget the ridiculous

more info


11/20/2024
DOGE Is a Great Idea. Trump Should Make It Permanent
DOGE represents a harbinger of deregulation for an incoming Trump administration, especially with Dogecoin enthusiast Elon Musk and Vivek Ramaswamy at the helm.

more info


11/20/2024
The DOGE Plan To Reform Government
Following the Supreme Court's guidance, we'll reverse a decadeslong executive power grab.

more info


11/20/2024
Could Trump Actually Get Rid of the Department of Education?
Getting rid of the agency would cause a lot of harm and wouldn't really change school curriculum.

more info


11/20/2024
How Dems Are Losing Tomorrow's Elections Today
America is outgrowing the Democratic Party.

more info


11/20/2024
Can a Fractured Democratic Party Learn the Lessons of 2024?
After a bruising campaign season and a humiliating defeat at the polls, this week saw Dems' internal conflicts spilling out into public view. Party insiders are now engaged in tit-for-tat Twitter battles that do nothing to offer the party a roadmap back to political contender status. Instead, they confirm normies' worst caricatures of Democratic dysfunction.

more info


11/20/2024
Pennsylvania Voters to Sen. Casey: 'It's Over, Bob'
Columnist David Marcus talks to voters in Bucks County and finds Democrats and Republicans agree that Sen. Bob Casey's refusal to concede is a bad look.

more info


11/20/2024
NC Republicans' Shameless New Power Grab
North Carolina voters spoke loud and clear two weeks ago when they elected Democrats to some of the most prominent statewide offices.

more info


11/20/2024
Trump Can and Should Fire Jerome Powell
Legacy media have been obsessing over whether President-elect Donald Trump can remove Jerome Powell, chairman of the Federal Reserve (the Fed). Jerome Powell recently came out and stated he would serve out his term - which ends in 2026. Further, Chairman Powell claims any attempt by President Trump to remove him is not "permitted under the law." Unfortunately for Chairman Powell, President-elect Trump can remove him - and he should - to make the federal bureaucracy respond to democratic pressures once again.

more info


11/20/2024
SecDef Austin: Women in Military Make U.S. Stronger
Austin in an exclusive interview with NBC News called women in the military a strong asset. Trump's choice for Secretary of Defense has cast doubt on women in combat roles.

more info


11/20/2024
Drone, Missile Defense Top Priorities for Next Defense Secretary
Pete Hegseth faces critical challenges in addressing U.S. vulnerabilities to advanced missile and drone threats as global tensions rise.

more info



Custom Search

More Politics Articles:

Related Articles

5 Financial Pressure Points To Evaluate During COVID Times


Financial pressure is a part of life for most people, and now the COVID-19 pandemic has brought new financial pressure points or exacerbated existing ones for many individuals and families.

Why Are People Complaining About Innovative COVID Treatments?


Gilead Sciences just announced it will charge $3,120 for a full course of Remdesivir, the first new FDA-approved treatment for COVID-19. Some knee-jerk members of Congress like Lloyd Doggett (D-Tex.) immediately condemned that price tag as "outrageous." The Institute for Clinical and Economic Review, a left-leaning nonprofit that releases its own recommendations of "fair" drug prices, claimed that Gilead could afford to price Remdesivir as low as $10 per course of treatment -- the cost of the raw ingredients used to make the drug.

Proposed Healthcare Reforms Will Not Help the Latinx Community


Joe Biden is officially the Democratic presidential nominee, all thanks to his moderate reputation.

Trade Enforcement Can Accelerate America's Economic Recovery


The stock market has largely rebounded from COVID-19 and American retail sales are improving steadily. Even more encouraging is that the U.S. unemployment rate fell for the fifth consecutive month in September. Each of these gains are sure signs that the Trump administration's economic response to the coronavirus crisis is working.

Drug Price Controls: Right Objective, Wrong Solution


This month, President Trump signed an executive order to reduce Medicare spending on prescription drugs. For each medication, Medicare will pay no more than the lowest price available in other developed countries.

Keep Thanksgiving, Family and Friends Alive


Joe Biden or Donald Trump will never visit me in my home, stand beside me at the funeral home or dance at my wedding. I will not be receiving any calls from either of them to pray for me during sickness or to check on how my children are doing. I probably will never sit in a room with them to visit, laugh and tell funny stories or just to hang out over a cup of coffee. I do not personally know either one. I welcome the opportunity to visit with either of them, but doubt it will happen.

The "E" Stands for “Excellence:” Remembering Walter E. Williams


Walter E. Williams, prolific author, piercing cultural commentator, old school economist (that’s a good thing), devoted husband, loving father, and long-time friend of Grove City College has passed from this world.

How Congress Can Really Fix Surprise Billing


House and Senate leaders recently agreed on legislation to end surprise medical bills as part of a big coronavirus relief package. President Trump signed it into law at the end of December.

A Federal Rule Will Reverse Strides in Cancer Treatment


"You've got cancer." That's one of the scariest sentences in the English language.

Biden Must Restore Seniors' Access to Essential Medicines


On January 19, Medicare officials announced a new payment model that could wreak havoc on the chronically ill.

Violence In America, Don't Be Surprised


The most recent attack at the United States Capitol will most likely insure a permanent fence and additional security. The attack which resulted in the loss of life for a long serving Capitol police officer and the attacker is another senseless violent act.

Protecting the Innovation that Protects Global Health


The most far-reaching healthcare policy decision of 2021 won't be made in Congress or the White House. It will be made at the World Trade Organization, which is considering a petition to waive all patent rights on Covid-19 vaccines.

Don't Repeat Europe's Vaccine Catastrophe


For many Americans, the calamitously slow vaccine roll-out in countries like Germany, France, and Italy comes as a surprise. After all, in the early days of the pandemic, Europe's response to the crisis seemed highly competent, especially compared to the United States.

A Full Plate for the New U.S. Trade Czar


The newly confirmed U.S. trade representative, Katherine Tai, is about as qualified as a person can be for the job. Which is a good thing, because she already faces a series of challenges.

Don't Let the US Import Europe's Failed Cancer Policies


With a majority in both the House and Senate and control of the Oval Office, Democratic leaders are excited about the prospect of making significant changes. One good example of this is the House Democrats' "Lower Drug Costs Now Act."